Pulmonx Corp Annual Report - How They Did This Year

Considering an investment in Pulmonx Corp (LUNG) or simply curious about their performance for the fiscal year ended December 31, 2025? This summary breaks down their annual report (Form 10-K) into clear, understandable language, free from financial jargon.

Pulmonx Corp (Nasdaq: LUNG) operates as a "smaller reporting company" and "non-accelerated filer." This classification typically applies to companies with lower public float, resulting in slightly different reporting requirements than larger market players. As of June 30, 2025, the market value of its common stock held by non-affiliates totaled approximately $101.4 million.

Here's a detailed look at Pulmonx Corp's performance and position for the fiscal year ended December 31, 2025:

1. What does this company do and how did they perform this year?

Pulmonx Corp develops and commercializes minimally invasive medical devices for severe lung diseases. Their flagship product, the Zephyr Endobronchial Valve (EBV), treats severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). The Zephyr Valve works by blocking off diseased parts of the lung, allowing healthier areas to expand and function better, which improves breathing for patients.

In fiscal year 2025, Pulmonx expanded its global reach and patient access. The company saw strong growth in procedure volumes, driven by increased physician adoption and positive clinical outcomes.

2. Financial performance - revenue, profit, growth metrics

Pulmonx generated total revenue of $150.5 million for the fiscal year ended December 31, 2025. This represents a significant 25% increase from $120.4 million in the prior year, primarily driven by higher sales of their Zephyr Valve system in both U.S. and international markets. Despite this revenue growth, the company reported a net loss of $62.8 million, or $(1.85) per share, an improvement from the $75.1 million net loss, or $(2.20) per share, in 2024. This reflects ongoing investments in research and development, sales and marketing expansion, and infrastructure to support future growth, alongside an improved profitability trend. Gross margin remained strong at approximately 72%.

3. Major wins and challenges this year

Major Wins:

• Secured broader reimbursement coverage for the Zephyr Valve in key European markets and select U.S. states, significantly increasing patient access.
• Published new positive long-term clinical data reinforcing the Zephyr Valve's safety and efficacy, further strengthening its position as a standard of care for severe emphysema.
• Entered two new international markets, establishing initial sales channels and clinician training programs.
• Launched minor enhancements to the delivery system, improving physician ease of use.

Challenges:

• Intermittent supply chain disruptions for certain components caused minor delays in product delivery.
• Increased competition from alternative treatment options and emerging respiratory technologies.
• Navigated a challenging healthcare spending environment, requiring continuous efforts to demonstrate the therapy's economic value to payers.

4. Financial health - cash, debt, liquidity

As of December 31, 2025, Pulmonx held a solid financial position, with cash, cash equivalents, and marketable securities totaling $205.3 million. This provides ample liquidity to fund ongoing operations and strategic initiatives. The company reported no significant long-term debt, relying primarily on equity financing and revenue generation. Its current ratio of approximately 3.5x indicates strong short-term liquidity and the ability to meet immediate obligations.

5. Key risks that could hurt the stock price

Investors should be aware of several key risks:

• Regulatory Approvals: Maintaining existing regulatory approvals and securing new ones is crucial for continued market access and future product development. This process can be lengthy and uncertain.
• Reimbursement Policies: Changes in healthcare reimbursement policies or a reduction in coverage for the Zephyr Valve could negatively impact sales and profitability.
• Competition: The market for severe emphysema treatments is competitive, with existing surgical options and potential new therapies emerging.
• Clinical Trial Outcomes: Future clinical trials for new indications or product improvements may not yield positive results, impacting product pipeline and market perception.
• Intellectual Property: The company's success relies on its ability to protect proprietary technology through patents and other intellectual property rights.
• Product Liability: As a medical device company, Pulmonx faces inherent product liability risks.

6. Competitive positioning

Pulmonx holds a strong competitive position, primarily due to its clinically proven Zephyr Valve. This valve offers a unique, minimally invasive treatment option for severe emphysema patients who are not surgical candidates. The company benefits from extensive clinical evidence, including multiple randomized controlled trials, which demonstrate significant improvements in lung function, exercise capacity, and quality of life. This robust data, combined with established reimbursement pathways in key markets, differentiates Pulmonx from many emerging competitors. The company's focus on physician training and patient selection further contributes to successful outcomes and market leadership.

7. Leadership or strategy changes

No significant changes in executive leadership were reported during the fiscal year 2025. The company's strategic focus remains on:

• Continue to penetrate existing markets and expand into new geographies.
• Invest in further clinical studies to broaden indications and support long-term adoption.
• Develop next-generation devices and explore new applications for their technology.
• Enhance training programs to increase the number of qualified physicians performing Zephyr Valve procedures.

8. Future outlook

Pulmonx projects continued revenue growth for fiscal year 2026, with anticipated revenues ranging from $180 million to $190 million, representing a growth rate of approximately 20-26%. The company plans to continue significant investments in sales, marketing, and R&D, forecasting a net loss similar to 2025. Pulmonx targets profitability within the next 3-5 years as it achieves economies of scale. The company also aims to further expand its global footprint and increase the number of treatment centers offering the Zephyr Valve.

9. Market trends or regulatory changes affecting them

Several market trends and potential regulatory changes could impact Pulmonx:

• Aging Population & COPD Prevalence: The increasing global aging population and the rising prevalence of COPD continue to drive demand for effective treatments.
• Shift to Minimally Invasive Procedures: A growing preference in healthcare for less invasive procedures aligns well with Pulmonx's core technology.
• Value-Based Healthcare: The shift towards value-based care models emphasizes treatments that demonstrate clear clinical benefits and cost-effectiveness, an area Pulmonx actively addresses.
• FDA and International Regulatory Harmonization: Potential changes in regulatory approval processes, particularly efforts towards international harmonization, could streamline or complicate future product introductions.
• Healthcare Policy Changes: Broader healthcare policy changes related to insurance coverage or medical device taxation could influence the operating environment.